

Corp. Off.: 502, Kanakia Atrium - 2,
Next to Courtyard Marriott Hotel,
Andheri Kurla Road, Andheri (East),
Mumbai - 400 093 (India)
Ph.: + 91 22 61933100 Fax : +91 22 61933114

Date: 08th June 2017

BSE Limited

Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai-400001

National Stock Exchange of India Ltd.

Exchange Plaza, C-1, Block G
Bandra Kurla Complex
Bandra (E), Mumbai-400051

Scrip Code: **533543**

Symbol: **BROOKS**

Sub: Resubmission of Audited Financial Results for the year ended 31.03.2017

Dear Sirs,

This is in continuation of our letter dated 29.05.2017 for submission of Financial Results as on 31.03.2017.

Earlier, we have submitted the Financial Results as per old format. Now, we are re-submitting the Financial Results as on 31.03.2017 as per line items given in Schedule III of the Companies Act, 2013.

Kindly take the same on record.

Thanking You,

Yours faithfully

For **BROOKS LABORATORIES LIMITED**



(Rajesh Mahajan)
Managing Director
DIN No. 02000634

Encl.: As above

Tel No : +91 1795 654001/02/03, Fax No :+91 1795 236939, E-mail : investors@brookslabs.net, Website: www.brookslabs.net
 Audited Financial Results for the Quarter/ Year Ended March 31, 2017

PART I

Particulars	Quarter Ended			Year Ended	Year ended
	31.03.2017	31.12.2016	31.03.2016	31.03.2017	31.03.2016
	(Audited)	(Unaudited)	(Audited)	(Audited)	(Audited)
1 Revenue					
(a) Revenue from Operations (Gross)	1,627.96	1,647.48	2,069.33	6,484.30	8,000.94
Less : Excise Duty (Refer Note 3)	195.70	239.60	-	730.32	-
Revenue from Operations (Net)	1,432.26	1,407.88	2,069.33	5,753.98	8,000.94
(b) Other income	4.92	3.94	21.76	12.27	156.10
Total Revenue	1,437.18	1,411.82	2,091.09	5,766.25	8,157.04
2 Expenses					
(a) Cost of materials consumed	974.39	1,004.50	1,248.42	3,664.91	5,259.55
(b) Changes in inventories of finished goods & work-in-progress	63.32	(87.94)	29.77	1.35	34.68
(c) Employee benefits expense	236.42	201.76	204.23	820.94	707.84
(d) Finance costs	32.52	25.35	10.16	100.94	79.44
(d) Depreciation and amortisation expense	69.81	33.51	29.15	167.20	116.00
(f) Other Expenses	185.86	162.97	212.01	704.78	890.53
Total expenses	1,562.32	1,340.15	1,733.74	5,460.12	7,088.04
3 Profit / (Loss) before exceptional and extraordinary items and tax (1-2)	(125.16)	71.67	357.35	306.13	1,069.00
4 Exceptional items	-	-	12.88	-	12.88
5 Profit / (Loss) before extraordinary items and tax (3+4)	(125.16)	71.67	370.23	306.13	1,081.88
6 Extraordinary items	-	-	-	-	-
7 Profit / (Loss) before tax (5-6)	(125.16)	71.67	370.23	306.13	1,081.88
8 Tax expense					
- Current tax	(21.28)	14.61	99.71	66.61	242.06
- MAT credit (Entitlement)/Utilised	(101.48)	4.08	(78.79)	(62.37)	(184.88)
- MAT credit (Entitlement) of earlier year	-	-	(60.39)	-	(60.39)
- Deferred tax	86.04	5.35	10.10	101.91	13.21
- Tax of earlier years	-	-	(62.75)	4.32	8.55
9 Net Profit / (Loss) after tax (6-7)	(88.44)	47.63	462.35	195.66	1,063.33
10 Paid-up equity share capital (Face Value Rs.10/- per share)	1,618.64	1,618.64	1,618.64	1,618.64	1,618.64
11 Reserve excluding Revaluation Reserves as per balance sheet of previous accounting year				10,586.37	9,523.04
12 Earnings per share of Rs.10/- each (not annualised):					
(a) Basic -in Rs.	(0.55)	0.29	2.86	1.21	6.57
(b) Diluted- in Rs.	(0.55)	0.29	2.86	1.21	6.57

Notes :

- The above results were reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on May 29, 2017.
- During the month of March 2017, company has commenced its commercial production of Vadodara unit, first sale invoice of vadodara unit is raised in April, 2017
- W.e.f 2nd June 2016, excise duty has been levied on the product manufactured at baddi unit at Himachal Pradesh which was exempted earlier by central government being backward state.
- The Company is mainly engaged in the business of "Pharmaceutical Formulations" and there is no other reportable business segment as per Accounting Standard (AS-17).

For Brooks Laboratories Ltd.

Managing Director

DIN NO. 02000634

5 The figures of the last quarter ended March 31, 2017 and March 31, 2016 are the balancing figures between audited figures in respect of full financial year and the published year to date figures up to the third quarter of the relevant financial year.

6 Figures of the previous period / year have been reclassified/ regrouped wherever necessary.

For and on behalf of the Board

Date : May 29, 2017
Place : Mumbai

Rajesh Mahajan
DIN No. : 02000634
Managing Director



Brooks Laboratories Limited

Statement of Assets and Liabilities as on March 31, 2017

(Rs. in Lacs)

Particulars	Year ended 31.03.2017	Year ended 31.03.2016
	(Audited)	(Audited)
A EQUITY AND LIABILITIES		
1 Shareholders' funds		
(a) Share capital	1,618.64	1,618.64
(b) Reserves and surplus	10,782.02	10,586.37
Sub-total - Shareholders' funds	12,400.66	12,205.01
2 Non-current liabilities		
(a) Long-term borrowings	1,080.51	34.24
(b) Deferred tax liabilities (net)	248.02	146.10
(c) Long-term provisions	97.54	76.18
Sub-total - Non-current liabilities	1,426.07	256.52
3 Current liabilities		
(a) Short-term borrowings	217.55	528.36
(b) Trade payables	1,836.40	1,571.60
(c) Other current liabilities	351.70	561.32
(d) Short-term provisions	76.80	130.87
Sub-total - Current liabilities	2,482.45	2,792.15
TOTAL - EQUITY AND LIABILITIES	16,309.18	15,253.68
B ASSETS		
1 Non-current assets		
(a) Fixed assets	11,858.96	10,319.39
(b) Non-current investments	2.00	2.00
(c) Long-term loans and advances	2,047.40	1,938.28
Sub-total - Non-current assets	13,908.36	12,259.67
2 Current assets		
(a) Inventories	769.89	668.89
(b) Trade receivables	1,149.17	1,891.44
(c) Cash and cash equivalents	183.69	222.58
(d) Short-term loans and advances	286.96	189.33
(e) Other current assets	11.11	21.77
Sub-total - Current assets	2,400.82	2,994.01
TOTAL - ASSETS	16,309.18	15,253.68

For Brooks Laboratories Ltd.



Managing Director

DIN No. 02000634

SGCO & Co. LLP

Chartered Accountants

Auditor's Report on Annual Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

**To The Board of Directors of
Brooks Laboratories Limited**

1. We have audited the accompanying statement of Financial Results of Brooks Laboratories limited ("the Company") for the quarter ended March 31, 2017 and year to date results for the period from April 1, 2016 to March 31, 2017 attached herewith ("the Statement"), being submitted by the company pursuant to the requirement of Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. This Statement, which is the responsibility of the Company's Management and approved by the Board of Directors, has prepared on the basis of the related financial statements which are in accordance with the Accounting Standards prescribed under section 133 of The Companies Act, 2013 read with the relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express an opinion on the Statement.
2. We conducted our audit in accordance with the Standards on Auditing issued by the Institute of Chartered accountants of India. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether statement is free from material misstatement.
An audit involves performing procedures to obtain audit evidence about the amounts and the disclosures in the Statement. The procedures selected depend on the auditor's judgment, including the assessment of the risks of material misstatements in the accompanying Statement, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the Company's preparation and fair presentation of the Statement in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness on the Company's internal control. An audit also includes evaluating the appropriateness of the accounting policies used and the reasonableness of the accounting estimates made by the management, as well as evaluating the overall presentation of the Statement.
We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.
3. In our opinion and to the best of our information and according to explanation given to us ,the statement;
 - (i) Is presented in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirement) Regulations, 2015; and
 - (ii) Gives a true and fair view in conformity with the aforesaid Accounting Standards and other accounting principles generally accepted in India of the net profit and other financial Information of the Company for the year ended 31st March 2017.

4A, Kaledonia-HDIL,
2nd Floor, Sahar Road,
Near Andheri Station,
Andheri (East),
Mumbai - 400 069. India

Tel.: +91 22 6625 6363
Fax: +91 22 6625 6364
E-mail: info@sgco.co.in
www.sgco.co.in



SGCO & Co. LLP

Chartered Accountants

4. The statement includes the results for the quarter ended 31st March 2017 being the balancing figure between the audited figures in respect of the full financial year and the published year to dated figures up to the third quarter of the current financial year which were subject to limited review by us.

For S G C O & Co. LLP

Chartered Accountants

Firm's Registration No.112081W/W100184



Shyamratan Singrodia

Partner

Mem. No. 49006

Place : Mumbai

Date: 29th May, 2017